Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. - Wikidata - wikimedia - TriplyDB

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

http://www.wikidata.org/entity/Q34570947

about

Antibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation Q24235340 Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy Antibiotics plus colony stimulating factors versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantation The intestinal microbiota and susceptibility to infection in immunocompromised patients Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn?The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004-2010: a surveillance-based study Febrile neutropenia in hematologic malignancies.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli.Antibacterial prophylaxis in neutropenic children with cancer Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: what is available in 2010?Once-daily, oral levofloxacin monotherapy for low-risk neutropenic fever in cancer patients: a pilot study in China.Bloodstream infections in neutropenic cancer patients: A practical update.Antibiotic prophylaxis for patients with acute leukemia.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.Management of metastatic germ cell tumors.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Prevention of febrile neutropenia: use of prophylactic antibiotics.Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.Antibiotic management of febrile neutropenia: current developments and future directions.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Supportive care in severe and very severe aplastic anemia.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncol Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions.Multidrug-resistant bacteria in hematology patients: emerging threats.Oral Ciprofloxacin Prophylaxis in Patients Undergoing High DoseTherapy and Autologous Hematopoietic Stem Cell Transplantation.Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.Prophylactic levofloxacin in pediatric neutropenic patients during autologous hematopoietic stem cell transplantation.An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome.

P2860

Q24186282-469C2294-6500-401C-A472-3924CC54E3B6 Q24200225-878F7171-CEE6-4DC6-9114-9840A901927E Q24235340-496D4642-FCCA-4A5E-8E06-C72676C82C1A Q24235345-E6AAD842-F6B4-4018-9FE9-396709C07D73 Q24241475-534014F3-0F22-4152-948A-ECFF36EB0FC6 Q24241680-A900E44B-9324-4884-B502-D934EB02A774 Q24241689-103AABBE-2745-4CD7-9835-F5067F3DEAB0 Q26862848-F28D1594-AED3-479C-BD62-9979D0951A5C Q28571264-E64526A3-AB0E-4524-A776-14A660FB4430 Q31125417-3F624217-A9A6-4483-B870-ECA7F687BC5C Q33559453-EBD2695D-1CD1-4D16-BD8F-5481278D992A Q34027816-AAE6E476-4D97-4DBA-8F32-84501B2543B9 Q34614712-EB927E71-ECEE-45D4-BA0D-615970E8C7FB Q34655730-76614407-E56D-4BF2-BA35-EC8C62CF4D66 Q34667166-D2195D8E-FBED-4DC1-A367-569729E3CD60 Q34670717-51A6F834-61D6-4ABE-B7E3-A3B6AA5305AE Q34783463-E95F6F98-599B-4F10-A56D-B64E6346C5E4 Q35010336-59E592F5-1B8B-4DE9-AF56-177BDB4204B2 Q35010346-DE6D2956-5B5E-4214-9D38-7ED3E86E784F Q35038916-0D464053-7336-456D-8B8F-337A3A7C89FF Q36913345-0B5E6063-512C-4FF6-984C-881306E5F737 Q37071680-4958CBCB-24B8-4887-B495-A405FD29FB76 Q37150434-D15FA2C6-C9C8-4A3A-AEA2-ECAC186F2A56 Q37159527-05D355E6-B194-4FEF-BB27-EB71E0341263 Q37323006-9DCFF000-1F38-41C1-BEFE-DD35795AE5E8 Q37363337-D27C9C23-0585-4C82-84C8-2308CF3040FA Q37504803-869061CF-156E-430C-8CB3-E5B22DCB4AED Q37708866-EFC8F863-0A1B-49E3-8708-39E614FFA639 Q37831314-FAF4F290-BD80-4836-B3C4-7C8EC04F46CF Q37931905-48B67D60-0C37-41D8-B936-6A89EFCA2466 Q38064773-DEF8304A-81EC-4CBB-AA57-FF4541D0C021 Q38081793-661BE46B-E154-4437-92DA-16422A589B5A Q38749061-BDEACB01-DBB3-460C-826D-8DE585F0909F Q38838498-FBE3899E-6514-48B2-91C2-C4A9460B81DA Q40067909-23197DD5-C040-488E-92DE-DA5E715B1D22 Q40129165-6039AC74-6B21-4124-B06D-3584B2DC3910 Q40139724-9D457F79-5954-4FC1-BB6F-93FDD13FA91B Q40335966-8E8D7CDD-96E4-4ED4-A624-0D1BC16A55D8 Q40335974-0A6C7276-36A7-44E8-9669-78ABC4862B3F Q40407884-A128A5D1-7794-462C-91CE-65AE90203B66

P2860

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

http://www.wikidata.org/entity/Q34570947

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@ast

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@en

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@nl

type

label

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@ast

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@en

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@nl

prefLabel

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@ast

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@en

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@nl

P1433

Q34570947-79330263-1958-489F-918E-C021A0BA8FC2

P1476

Q34570947-2C064064-49B0-4A5A-A0B8-652D3E46C48C

P2093

Q34570947-55D93A24-6A0A-4EFD-B075-D3AA5F9EC978

Q34570947-AE5D5FA4-C71A-4678-A8AE-CF09FC305252

Q34570947-BFD3F870-5676-4B89-9312-B88D3E273196

Q34570947-E87B7B04-EF8F-4DDA-B2CD-DB80C29BCE63

P2860

Q34570947-28B0F644-B140-4CBD-B3D4-99A9730F52B9

Q34570947-32135140-DD60-4835-AF45-B0D89AECF622

Q34570947-34C4CDCE-055A-4FA0-AA07-0204AB8D7B94

Q34570947-59138A4D-AB1C-4659-B275-6EB9FD443055

Q34570947-6E660615-CD33-453E-A8F2-1026CDB99C27

Q34570947-D276837F-75D3-4FE4-8EA4-3248AE0AC0E9

Q34570947-D72B2A9C-A042-4404-894B-600C0FB3C382

Q34570947-DA726952-1006-4AE6-93D2-2185065C80D0

P304

Q34570947-45185CF3-E9C8-47E4-A0B5-C0B2CB42AF4E

P31

Q34570947-64F0ADBA-0B76-4ABF-8436-2C5689C65F1F

P356

Q34570947-5A513315-AD0E-4845-8F84-64FB4EAAC7D9

P407

Q34570947-5208AEB5-9829-4ADA-A53C-329FF604A283

P433

Q34570947-6000994E-EEE8-4E7E-A12E-98E419C4667F

P478

Q34570947-8E5711B8-6F1A-4DEC-889F-D5870D75870D

P50

Q34570947-284EE756-A8B3-485D-816F-F4FC2289C5E0

Q34570947-40AC56FA-06B7-43C5-A14F-1EE1657A0CB9

Q34570947-7D2311DF-E0B0-4B1B-82A9-182A823506B9

P577

Q34570947-2E83A9FA-8462-452D-A326-BC507695C3F3

P5875

Q34570947-84812582-1DE9-48AD-AC7C-B17B91D8B22B

P698

Q34570947-A51C7339-89A6-41A3-836E-30F156284CCE

P921

Q34570947-35846288-EBFB-440C-A72A-25DED7AE8785

P356

P1433

P1476

Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.

@en

P2093

Anat Gafter-Gvili

http://www.w3.org/2001/XMLSchema#string

Giampaolo Bucaneve

http://www.w3.org/2001/XMLSchema#string

Michael Cullen

http://www.w3.org/2001/XMLSchema#string

Winfried V Kern

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.

Clostridium difficile ribotype 027, toxinotype III, the Netherlands.

How do you choose antibiotic treatment?

Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia. The Enoxacin Prophylaxis Study Group.

Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines.

P304

1743-1751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.22205

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Leonard Leibovici

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6815856

http://www.w3.org/2001/XMLSchema#string

P698

16977651

http://www.w3.org/2001/XMLSchema#string

P921